Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | FDPS | P14324 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA4 | P22748 | 1/20 | 0.66 |
| ▸ | CA6 | P23280 | 1/20 | 0.66 |
| ▸ | CA5A | P35218 | 1/20 | 0.66 |
| ▸ | CA7 | P43166 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.66 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.66 |
| ▸ | TTR | P02766 | 1/20 | 0.66 |
| ▸ | APP | P05067 | 4/20 | 0.64 |
| ▸ | MMP1 | P03956 | 4/20 | 0.64 |
| ▸ | MMP2 | P08253 | 2/20 | 0.64 |
| ▸ | MMP3 | P08254 | 2/20 | 0.64 |
| ▸ | MMP9 | P14780 | 2/20 | 0.64 |
| ▸ | MMP12 | P39900 | 2/20 | 0.64 |
| ▸ | MMP13 | P45452 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5685199 | 1.00 | KDM4E (0.67) | KDM4ELMNAFDPSCA12CA4 | |
| SCHEMBL5685437 | 0.95 | FDPS (0.74) | KDM4ELMNAFDPSCA12CA4 | |
| SCHEMBL5685435 | 0.95 | FDPS (0.74) | KDM4ELMNAFDPSCA12CA4 | |
| SCHEMBL5688117 | 0.94 | KDM4E (0.76) | KDM4ELMNAFDPSCA12CA4 | |
| SCHEMBL5688120 | 0.94 | KDM4E (0.76) | KDM4ELMNAFDPSCA12CA4 | |
| SCHEMBL5687914 | 0.92 | LMNA (0.80) | KDM4ELMNAFDPSCA12CA4 | |
| SCHEMBL5687918 | 0.92 | LMNA (0.80) | KDM4ELMNAFDPSCA12CA4 | |
| SCHEMBL1549322 | 0.88 | LMNA (0.63) | KDM4ELMNAFDPSCA12CA4 | |
| SCHEMBL1549319 | 0.88 | LMNA (0.63) | KDM4ELMNAFDPSCA12CA4 | |
| SCHEMBL16319134 | 0.88 | LMNA (0.63) | KDM4ELMNAFDPSCA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060122064-A1 | Amides and method for plant diseases control with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1640360-A1 | AMIDES AND METHOD FOR PLANT DISEASE CONTROL WITH THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-1577290-A1 | AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
| WO-1997000249-A1 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | CBR3, C5, CLN6 | KDM4E 3575/4885LMNA 2837/4885FDPS 1365/4885 |
| US-20060122064-A1 | Amides and method for plant diseases control with the same | ARG1, ARGLU1, ARG2 | KDM4E 2492/4885LMNA 1009/4885FDPS 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.